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ABSTRACT
Background. Alveolar soft part sarcoma (ASPS) is an exceed-
ingly rare and orphan disease, without active drugs approved in
the front line. Pazopanib and trabectedin are licensed for sar-
coma treatment from second-line, but very little and contradic-
tory data are available on their activity in ASPS. Lacking ongoing
and/or planned clinical trials, we conducted a multi-institutional
study involving the reference sites for sarcoma in Europe, U.S.,
and Japan, within the World Sarcoma Network, to investigate
the efﬁcacy of pazopanib and trabectedin.
Materials and Methods. From May 2007, 14 of the 27 centers
that were asked to retrospectively review their databases had
identiﬁed 44 advanced ASPS patients treated with pazopanib
and/or trabectedin. Response was evaluated by Response Eval-
uation Criteria in Solid Tumors 1.1. Progression-free survival
(PFS) and overall survival (OS) were computed by Kaplan-Meier
method.
Results. Among 30 patients who received pazopanib, 18 were
pretreated (13 with other antiangiogenics). Response was
evaluable in 29/30 patients. Best responses were 1 complete
response, 7 partial response (PR), 17 stable disease (SD), and 4
progressions. At a 19-month median follow-up, median PFS
was 13.6 months (range: 1.6–32.21), with 59% of patients
progression-free at 1 year. Median OS was not reached.
Among 23 patients treated with trabectedin, all were pre-
treated and evaluable for response. Best responses were 1 PR,
13 SD, and 9 progressions. At a 27-month median follow-up,
median PFS was 3.7 months (range: 0.7–109), with 13% of
patients progression-free at 1 year. Median OS was 9.1 months.
Conclusion. The value of pazopanib in advanced ASPS is con-
ﬁrmed, with durable responses, whereas the value of trabecte-
din appears limited. These results are relevant to deﬁning the
best approach to advanced ASPS.The Oncologist 2018;23:62–70
Implications for Practice: This retrospective study, conducted among the world reference centers for treatment of sarcoma,
conﬁrms the value of pazopanib in patients with advanced alveolar soft part sarcoma (ASPS), with dimensional and durable
responses, whereas trabectedin shows a limited activity. Alveolar soft part sarcoma is resistant to conventional cytotoxic
chemotherapy. Pazopanib and trabectedin are licensed for treatment of sarcoma from second line; in the lack of prospective clinical
trials, these results are relevant to deﬁning ASPS best management and strongly support initiatives aimed at obtaining the approval
of pazopanib in the front line of the disease.
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Sarcomas
INTRODUCTION
Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma
(STS) that carries a speciﬁc t(X;17)(p11;q25), involving a
ASPSCR1-transcription factor E 3 (TFE3) fusion [1, 2]. The natu-
ral history of this tumor is characterized by an indolent behav-
ior, coupled with a paradoxical high metastatic rate. As a result,
most patients eventually require medical therapy. Although
conventional anthracycline-based chemotherapy is inactive in
this disease [1, 3–5], ASPS was reported to be sensitive to anti-
angiogenic agents like sunitinib, cediranib, and, more recently,
anlotinib [6–10]. These antiangiogenic agents can induce
dimensional responses and durable disease control in 35% and
60% of patients, respectively, across different published stud-
ies. Unfortunately, none of these drugs are approved for the
treatment of ASPS, and no active agents have regulatory
approval in the front line.
Trabectedin and pazopanib are among the medical agents
licensed for treatment of STS from second line after failure to
anthracyclines, but data on their activity in patients affected by
ASPS are scant. Trabectedin is a marine-derived product charac-
terized by a complex and unique mechanism of action, affecting
multiple key processes in tumor cell replication and death [11],
and targeting tumor microenvironment [12, 13]. Trabectedin
approval in STS is based on the results of two trials carried out
in adult patients with a diagnosis of liposarcoma or leiomyosar-
coma after failure of prior conventional chemotherapy [14, 15].
In the ﬁrst study, one trabectedin regimen was superior to
another (with evidence of a longer progression-free survival
[PFS] in favor of a 24-hour infusion regimen, as compared with
a 3-hour infusion schedule) [14]. In the other study, trabectedin
was superior to dacarbazine in the same histologies in terms of
PFS, although not in terms of overall survival (OS) [15].
Pazopanib is an antiangiogenic agent, inhibiting vascular
endothelial growth factor receptors (VEGFR) 1–3, that was ini-
tially investigated in sarcoma within a phase 2 trial published
by Sleijfer and colleagues in 2009 [16, 17]. In the phase 3 study
in nonadipocytic STS that followed the phase 2 trial, the
median PFS was 4.6 months for pazopanib, compared with 1.6
months for placebo, with an OS of 12.5 months versus 10.7
months [18].
In patients affected by ASPS, there are few case reports
stating that trabectedin can achieve the stabilization of the
tumor without evidence of tumor shrinkage. Unfortunately,
those reports did not detail if treated patients were progressive
or not before starting the drug [19–21]. Conversely, Nakamura
and colleagues recently described 4 Response Evaluation Crite-
ria in Solid Tumors (RECIST) responses of 12 (33%) ASPS
patients treated with pazopanib [22], while a study from
Korea noted 1 response among 6 ASPS patients treated with
the drug within a prospective trial that was unfortunately
closed early due to slow accrual (Clinicaltrials.gov reference
NCT02113826) [23].
Due to the rarity of ASPS and the lack of prospective trials,
we conducted a retrospective multi-institutional case-series
analysis among reference centers for treatment of STS, with
the support of the World Sarcoma Network, to investigate the
activity and the efﬁcacy of trabectedin and pazopanib in
advanced ASPS patients. The results presented herein are
important to reﬁne the best clinical management of the disease
in the metastatic setting.
MATERIALS AND METHODS
We considered all consecutive patients with locally advanced
and/or metastatic ASPS treated with trabectedin (group A)
and/or pazopanib (group B), in front or further lines, outside
clinical trials, from May 2007 to November 2016. Patients were
treated at 14 international reference centers for treatment of
STS from Europe, U.S., and Japan, selected among 27 institu-
tions that were asked to review their databases within the
World Sarcoma Network effort. Only cases in which diagnosis
of ASPS was histologically proven and conﬁrmed by each insti-
tutional pathologist were included in the study. All patients pro-
vided a written informed consent to the treatment with
trabectedin and/or pazopanib. Approval by each Institutional
Review Board was also required.
Treatment
Patients in group A received intravenous trabectedin, at a start-
ing dose ranging from 1.3–1.5 mg/m2 - (at investigator’s discre-
tion, with a maximum dose of 2.6 total mg per cycle), given in
24-hour continuous infusion, with glucocorticoid premedica-
tion, every 3 weeks, until progression or toxicity.
Patients in group B were administered pazopanib orally, at
the dose of 800 mg per day (either 800 mg oral daily or 400 mg
twice a day), continuously, until progression or toxicity.
Clinical Assessment
Performance status, biochemistry, and blood count were eval-
uated at baseline and monitored throughout the study period.
Adverse events were recorded. Disease status was assessed by
whole body computed tomography (CT) scan and/or a CT/
magnetic resonance imaging (MRI) of the sites of disease at
baseline and then repeated every 2–3 months, at the discretion
of the treating physician.
Efficacy Assessment
Response to treatment was assessed by RECIST, version 1.1
[24]. Overall survival and PFS were estimated on SAS University
Edition software (SAS Institute, Cary, NC, https://www.sas.com/
en_us/home.html) and survival analyses were conducted by
the Kaplan-Meier method. Patients without evidence of pro-
gression and interrupting treatment with trabectedin (group A)
and with pazopanib (group B) for any reason were censored at
the last follow-up. Patients alive or lost to follow-up were cen-
sored at the last contact.
RESULTS
We retrospectively identiﬁed 23 patients treated with trabecte-
din (group A) and 30 patients treated with pazopanib (group B).
Four patients were treated sequentially with trabectedin and
pazopanib and are included in both groups. Tables 1 and 2 sum-
marize patient characteristics and clinical ﬁndings.
Group A: Trabectedin
All patients completed their treatment (22 progressive; 1 other)
and all were evaluable for response. Mean age was 32 (range:
19–48) years. Performance status was  3 in all cases. All
patients, except for one who was treated for a locally advanced
tumor, had metastatic disease. Twenty-one of 23 patients had
received at least 1 prior line of medical therapy before starting
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trabectedin>1 line in 17 patients). The information on the evi-
dence of progression before trabectedin initiation was available
in 11 cases, all progressive.
Starting dose of trabectedin was 1.2, 1.3, and 1.5 mg/m2 in
4, 5, and 14 cases, respectively, administered every 3 weeks.
Median number of cycles administered was four. Overall, tra-
bectedin toxicity was as expected and was fairly well tolerated
[grade (G)  3 non-hematologic toxicity 4; G 3 hematologic
toxicity 5]. None of the patients had to deﬁnitively stop their
treatment due to toxicity. In all patients, toxicity resolved upon
holding trabectedin.
Response
Best RECIST responses with trabectedin were 1 partial response
(PR), 13 stable disease (SD), and 9 progressive disease (PD), for
an overall response rate (ORR) of 4.3%.
At a 27-month median follow-up, the median OS was 9.1
months, with 16 patients dead at the time of the present analysis
(Fig. 1A). Median PFS by RECIST was 3.7 months (range: 0.7–109;
Fig. 2A), with 13% of patients progression-free at 12 months.
Group B: Pazopanib
At the time of the present analysis, 23 patients had completed
the treatment with pazopanib (19 progression; 4 toxicity), while
7 (23%) were still on therapy. Twenty-nine of 30 patients were
evaluable for response.
Mean age was 33 (range: 22–68) years. Performance status
was 0–2 in all patients. All patients had metastatic disease.
Twelve patients were treatment-na€ıve at the time of starting
pazopanib, and 18 were pretreated with at least 1 previous reg-
imen. Thirteen (43%) patients had already received another
antiangiogenic drug before starting pazopanib. The evidence of
progression before starting pazopanib was documented in 13
out of 17 cases for which this information was available, and
the remaining 4 patients were stable.
All patients started pazopanib at the dose of 800 mg/day,
except for three patients who received 600 mg/day. Median
number of cycles was 12 (range: 2–33). Pazopanib was fairly
well tolerated (G 3 non-hematologic toxicity: 6; G 3 hema-
tologic toxicity: 0). Four patients deﬁnitively stopped pazopanib
due to side effects. In all patients, toxicity resolved upon pazo-
panib discontinuation.
Response
Best response to pazopanib by RECIST was: 1 complete
response (CR), 7 PR, 17 SD, and 4 PD (Fig. 3), for an ORR of
27%. Notably, three patients responded to pazopanib after fail-
ure of another antiangiogenic agent (Fig. 4).
The median OS was not reached at the time of this analysis
(Fig. 1B). At a 19-month median follow-up, the median PFS by
RECIST was 13.6 months (range: 1.6–32.21). The PFS at 12
months was 59% (Fig. 2B).
Progression-free survival analysis stratiﬁed by the extent of
the response showed a signiﬁcantly better outcome in patients
achieving a RECIST CR and/or PR (8 cases) in comparison with
those who had only an SD (17 cases; median PFS: not reached
vs. 13.5 months, respectively; median OS: not reached) or a PD
(4 cases; median PFS: 4.6 months; median OS: not reached; Fig.
5). A comparison between patients na€ıve to and pretreated
with other antiangiogenics showed a trend towards a better
PFS in untreated patients (median PFS: 14.4 vs. 12.2 months,
respectively; supplemental online Fig. 1).Ta
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DISCUSSION
Our multi-institutional retrospective study collected the two
largest series currently available of patients affected by
advanced and/or metastatic ASPS and treated with trabectedin
or pazopanib, including 30 and 23 cases, respectively. This study
conﬁrms the activity of pazopanib in patients with advanced
ASPS, with 27% ORR by RECIST, a median PFS of 13.6 months,
and 59% of patients progression-free at 12 months. Responses
to pazopanib were also detectable in 3 of 13 patients with sec-
ondary resistance to other antiangiogenics. By contrast, the
Figure 1. Overall survival curve of patients treated with trabectedin and with pazopanib. At a 27-month median follow-up, the median OS
of patients treated with trabectedin (A) was 9.1 months (range: 2.9–109). At a 19-month median follow-up, the median OS of patients
treated with pazopanib (B) was not reached (range: 2.1–32.2).
Abbreviation: OS, overall survival.
Figure 2. Progression-free survival curve of patients treated with trabectedin and with pazopanib. At a 27-month median follow-up, the
median PFS by Response Evaluation Criteria in Solid Tumors (RECIST) was 3.7 months (range: 0.7–109) for patients treated with trabecte-
din (A). In the group of patients treated with pazopanib (B), the median PFS by RECIST was 13.6 months (range: 1.6–32.2) as evaluable at
a median follow-up of 19 months.
Abbreviation: PFS, progression-free survival.
Figure 3. Response to pazopanib. Axial, contrast-enhanced computed tomography scans in a patient affected by intra-abdominal metasta-
sis from an alveolar soft part sarcoma of the lower limb, at baseline and after six cycles of treatment with pazopanib, when a Response
Evaluation Criteria in Solid Tumors partial response was achieved.
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value of trabectedin in this series looked limited, with only a
single RECIST response (ORR 4.3%), a 3.7-month median PFS,
and 13% of patients free from progression at 12 months.
Alveolar soft part sarcoma is an extremely rare disease. Its
rarity makes it challenging to conduct prospective clinical trials,
as the premature closure of a Korean study on pazopanib due
to lack of recruitment recently demonstrated [23]. This con-
ﬁrms that collaborative efforts are of major importance. With
all the limitations of a retrospective study, our case-series anal-
ysis provides new information on the activity of two agents
that are available for STS in daily clinical practice.
The activity of trabectedin appeared limited, once more
underscoring the low sensitivity of ASPS to cytotoxics. Com-
pared with available reports [19–21], in our series trabectedin
did not achieve prolonged disease control in most patients,
with only three cases remaining stable while under treatment
for > 12 months. Of course, one should consider the high pro-
portion of heavily pretreated patients.
By contrast, our study conﬁrms the role of antiangiogenics
in ASPS. Of note, unfortunately, none of the agents with antian-
giogenic activity tested in ASPS so far are approved for treat-
ment of the disease in the front line, and pazopanib is the only
antiangiogenic drug formally registered for treatment of STS,
after failure on anthracycline. The results of a randomized trial
on cediranib in ASPS will be available soon and, if positive, will
possibly pave the way to the registration of another active drug
for this tumor. The antitumor effect of pazopanib in this series
was somewhat inferior to what has been reported on sunitinib
and cediranib, both in terms of ORR (27% for pazopanib vs.
35%–60% for cediranib and sunitinib) and duration of response
Figure 4. Response to pazopanib after secondary resistance to sunitinib. Axial, contrast-enhanced computed tomography scans in a patient
affected by lung metastases from a retroperitoneal alveolar soft part sarcoma. (A, B): The initial response to sunitinib followed by a secondary
progression marked by the appearance of new lung lesions (C, red circle). (D): Afterward, patient was started on pazopanib with a new response.
Figure 5. Progression-free survival and OS analysis stratiﬁed by the extent of Response Evaluation Criteria in Solid Tumors (RECIST) response.
Patients whose best response was a CR or a PR by RECIST were grouped together (group A, CR/PR patients: 8, blue line in the graph) and
compared with those who showed an SD (group B, SD patients: 17, red line) and those who progressed (group C, PD patients: 4, green line).
(A): Median PFS (range) was not reached (3.6–32.2), 13.5 months (1.6–19.9), and 4.6 months (1.7–14.4) in group A, B, and C, respectively.
(B): Median OS was not reached in all groups, with all patients of group A alive at the time of the present analysis (blue line).
Abbreviations: CR, complete response; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response;
SD, stable disease.
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(13-month median PFS in case of pazopanib vs. 15–19 months
with sunitinib in different series) [6–9, 26]. One can provide
only tentative explanations. Forty percent of patients in our series
had been previously treated with another antiangiogenic agent
and this may have limited, at least in part, the effect of pazopanib,
although mechanisms of resistance to antiangiogenics in ASPS are
unknown and could not be investigated retrospectively in this
multi-institutional series. In fact, a trend towards a better out-
come was detected in our study when the PFS of patients pre-
treated with pazopanib before starting pazopanib was compared
with the PFS of those na€ıve to antiangiogenic agents (median PFS
12.2 vs. 14.4 months). On the other hand, three patients included
in our study responded to pazopanib after failure on other antian-
giogenic agents. This observation conﬁrms that, at least in some
cases, the evidence of resistance to a given antiangiogenic does
not prevent the activity of another drug of the same class. Con-
versely, the different spectrum of targets inhibited by various anti-
angiogenics could be responsible for a different degree of
antitumor effect. In particular, sunitinib has a broader kinase pro-
ﬁle compared with pazopanib, which is a “purer” antiangiogenic
drug. Sunitinib has activity against platelet derived growth factor
receptor (PDGFR)a, PDGFRb, KIT, VEGF receptors 1–3 (VEGFR1–3),
fms-like tyrosine kinase 3 (FLT3), and, notably, macrophage
colony-stimulating factor receptor 1 (MCSFR1) [26], whereas
pazopanib is a more selective VEGF-signaling inhibitor [16]. Over-
all, the mechanisms underlying the response to sunitinib, cedira-
nib, anlotinib, and pazopanib in ASPS remain under evaluation.
The antiangiogenic effect of this class of agents may well target
the peculiar vasculature of ASPS [1], sustained by the
translocation-related activation of the lactate pathway, as
described by Goodwin et al. [27]. In addition to their antiangio-
genic impact, a direct antitumor effect due to the inhibition of
VEGFR, PDGFR, and rearranged during transfect (RET) expressed
by the tumor cells was described [8]. Finally, Kummar et al. intri-
guingly showed on tumor biopsies from eight patients treated
with cediranib that the antitumor effect of this agent induced the
downregulation of genes related to myeloid inﬁltrate and vasculo-
genesis [7]. Myeloid inﬁltration has also been proved by another
group, which showed the presence of myeloid cells both along
the tumor vessels and interspersed within the tumor cells
[28–30]. The role of tumor-inﬁltrating myeloid cells in the forma-
tion and maintenance of abnormal blood vessels in tumors is well
known [31]. These observations suggest an immunomodulatory
role of this class of drugs in addition to the antiangiogenic and
direct antitumor effect that could be enhanced when agents with
a greater activity against MCSFR1, such as sunitinib, are adminis-
tered. These data also suggest that immunomodulation could
play a role in this sarcoma type, and that combination of immu-
notherapeutic agents such as immune checkpoint inhibitors and
antiangiogenic agents may be worth exploring, as is being done
in ongoing clinical trials.
CONCLUSION
These data conﬁrm that pazopanib is active in patients with
advanced ASPS, whereas the value of trabectedin seems to be
limited. Collaborative efforts are of major importance in
improving the management of people with very rare sarcoma
subtypes. In an extremely rare disease where cytotoxics are
clearly ineffective, we believe that antiangiogenics should be
available for clinical use as ﬁrst-line medical options.
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